200 7.6/au CNE) T.6/au

HE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In re application of

Jean PLOUET et al.

BOX AF

JUL 1 6 2001

Serial No. 09/091,561

GROUP 1644

TECH CENTER 1600/2900

Filed August 21, 1998

Examiner G. Ewoldt

ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF AS DRUGS

AMENDMENT AFTER FINAL REJECTION

Commissioner for Patents

Washington, D.C. 20231

Sir:

Responsive to the Official Action of March 12, 2001, please amend the above-identified application as follows:

IN THE CLAIMS:

Amend claim 30 as follows:

- 30. (thrice amended) Anti-idiotypic antibody according to claim 25 produced by the following steps:
 - a) purified VEGF is injected into an animal,
- b) blood is withdrawn to recover purified Ig containing specific anti-VEGF IgG, and then in an optional stage the specific anti-VEGF IgG are purified from the purified Ig,
- c) said purified Ig or said purified anti-VEGF IgG are injected into an animal of the same origin as that used for injection of the VEGF,
- d) blood is withdrawn to recover the total Ig, and then to subject the total Ig to two immunoadsorptions:

Do not Enter SP2